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Unfractionated heparin is the anticoagulant of choice for cardiac surgery that requires cardiopulmonary bypass. However, it can
cause serious side eﬀects like heparin-induced thrombocytopenia (HIT), an immune-mediated process where antibodies are directed
against heparin and platelet 4 complexes. In such cases, alternative pharmacologic strategies are implemented to facilitate safe bypass
conditions. A woman with severe decompensated heart failure was heparinized for intra-aortic balloon pump and subsequent LVAD
placement. On day 6, a fall in platelets from 113,000 to 26,000 was noted. She was diagnosed with HIT. Heparin was discontinued and
replaced with an argatroban infusion for the duration of her care until heart transplantation was completed. We review the
mechanism, diagnosis, and complications of HIT. We discuss cardiopulmonary bypass and its relation to heparin, HIT, and heparin
alternatives. We discuss argatroban’s relevant pharmacology, clinical use, advantages, and disadvantages.

1. Introduction
Patients undergoing cardiac surgery frequently require
cardiopulmonary bypass (CPB) to isolate the heart for a
motionless, bloodless surgical ﬁeld. Anticoagulation is one
of the key steps in preparing the patient for CPB. Unfractionated heparin (UFH) is the anticoagulant of choice for
cardiac surgery and is used to prevent thrombin generation
and hence prevent clotting in the extracorporeal circuit.
However, it can cause serious side eﬀects like heparin-induced thrombocytopenia. Type 2 HIT is an immune-mediated process where antibodies are directed against heparin
and platelet 4 complexes (PF4), resulting in a >50% fall in
platelets and thrombosis after 5–10 days of heparin therapy.
Despite the resultant fall in platelets, patients present with an
increased risk of thrombosis [1]. We present a case of new
onset HIT with biventricular failure and acute renal failure

for urgent heart transplantation, which elicited the problems
one may face when using argatroban during CPB.

2. Case Summary
A 28-year-old woman with postpartum cardiomyopathy was
admitted for severe decompensated heart failure (EF < 15%).
Subsequently, she developed acute renal failure with creatinine levels rising from 1.0 to 2.9 mg/dL during hospitalization. She was started on inotropes and vasopressors,
and intra-aortic balloon pump and LVAD were placed
through heparinization. However, the patient continued to
deteriorate requiring an urgent transplant. On day 6, a fall in
platelets from 113,000 to 26,000 was noticed. Heparin was
discontinued, and the patient was started on argatroban to
attain aPTT 2-3 times baseline. After availability of a suitable
donor, the patient was scheduled for heart transplant on day
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10. Preoperatively, the labs were as follows: hemoglobin:
8 g/dl; platelets: 110000; creatinine: 2 mg/dl; PT: 10.9; and
aPTT: 60.1. Given the timing and magnitude of the platelet
count decline, along with its resolution after heparin cessation, the need for further laboratory investigation was
deemed not necessary, and the patient was diagnosed with
HIT. Two peripheral intravenous lines, 16G and 18G, and a
20G right radial arterial line were placed, followed by central
venous catheterization. Intraoperatively, induction and intubation were uneventful. After sternotomy, a loading dose
of argatroban 200 mcg/kg was administered to reach the
target ACT > 400 (activated clotting time). ACT values were
derived utilizing the point-of-care Hemochron Signature
Elite, whole blood microcoagulation system. Once
ACT >400, the patient was placed on CPB. This was followed
with an infusion of argatroban at 3.5 mcg/kg/min initially
and then titrated to 3 mcg/kg/min as guided by ACT. The
infusion was continued until the patient was successfully
weaned from CPB. During surgery, no clots were noted in
the extracorporeal circuit, and postoperatively, there were
no thrombotic and hemorrhagic complications. aPTT normalized 23 hours after stopping argatroban. The postoperative course was signiﬁcant only for line sepsis requiring a
prolonged course of antibiotic therapy and oliguria for
which the patient was being hemodialyzed prior to surgery.

3. Discussion
HIT is a potentially life-threatening immune-mediated
disorder that can lead to widespread thrombosis in 1–3% of
patients exposed to unfractionated heparin after cardiac
surgery [2]. In type 2 HIT, a greater than 50% reduction in
platelets is observed 5–10 days after heparin therapy and is
closely associated with the initiation of thrombosis, and the
platelet count begins to rise only after discontinuing heparin
[3, 4]. The magnitude of fall in platelet count is an important
risk factor for the development of thrombosis. Bleeding is
not commonly seen in these patients, and the observed
thrombocytopenia is due to the removal of activated platelets
and antibody-coated platelets by the reticulo-endothelial
system [3]. When clinical suspicion for HIT is high, in
addition to stopping heparin, nonheparin anticoagulants
should be started to prevent further development of
thrombosis. The diagnosis of HIT is a clinicopathological
one, and various clinical scoring systems have been used to
predict the likelihood of HIT [2]. Use of anti-PF4-heparin
enzyme immunoassay and a functional test like serotoninrelease assay increase the diagnostic accuracy for HIT [5].
Laboratory diagnosis, although conﬁrmatory, may be
delayed, and thus necessitates a clinical diagnosis of HIT.
These patients will require an alternative form of anticoagulation before going on bypass. Commonly used agents
include argatroban, bivalirudin, fondaparinux, and danaparoid, and they act by inhibiting thrombin generation.
However, their use can cause certain concerns in patients
scheduled for cardiac surgery. The presence of acute kidney
injury in this patient permitted only the use of argatroban as
both lepirudin and danaparoid are mainly excreted in the
kidneys [3]. The use of argatroban for CPB as an alternative
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to heparin has been explored in recent times, but there are
many challenges in the form of lack of dosing guidelines and
absence of an antidote. Currently, argatroban has been
approved for use in HIT for percutaneous coronary intervention procedures, but its use for CPB is oﬀ label [6].
Argatroban is a small synthetic molecule, which inhibits
both clot bound and free thrombin. It reaches steady state
plasma quickly with a predictable dose-response eﬀect and
correlates with the desired anticoagulant eﬀect [7]. It has a
short half-life of about 45 minutes and allows early reversibility of the anticoagulation eﬀect. However, hemodilution during CPB may alter the pharmacokinetics, making
the response less predictable. This may lead to inadequate
anticoagulation during CPB or excessive bleeding in the
postoperative period. Other properties that make argatroban
a suitable alternative are the lack of cross reactivity with HIT
antibodies and that argatroban itself does not induce antibodies that could alter its clearance [7]. The eﬃcacy of the
drug is monitored with aPTT at low doses and ACT at higher
doses. While ACT is commonly used to monitor anticoagulation during CPB, the ACT required to prevent clot
formation is still unclear. There have been reports of clot
formation in the circulation even with an ACT of 495
seconds, and it has been recommended that ACT be kept in
the range of 500–600 seconds [8]. The commonly used tests
such as aPTT and ACT have a curvilinear dose relationship
with plasma direct thrombin inhibitor (DTI) concentration,
making it diﬃcult to predict the required level of anticoagulation [9]. This probably could be the reason for
thrombosis during CPB even with ACT >400 seconds. In our
case, we were able to maintain an ACT >400 seconds without
any evidence of clotting in the extracorporeal circuit. Factors
such as hemodilution and hypothermia besides argatroban
concentration in the circulation inﬂuence the ACT values.
Keeping the ACT at a higher range could be a probable
solution to prevent clot formation, but it runs the risk of
increased chances for postoperative bleeding because of the
longer duration required for ACT to normalize [6]. It takes
2–4 hours for the aPTT to normalize after discontinuing the
drug, but in our case, it took about 23 hours probably because of the altered hemodynamics during CPB. However, it
had little bearing on bleeding in the postoperative period.
DTI speciﬁc assays like Ecarin clotting time (ECT) have
shown to better correlate with DTI plasma concentration
than ACT [10] and have shown intraoperative ECT monitoring during CPB may be a safer alternative. Another
disadvantage with using argatroban is the absence of an
antidote in situations of life-threatening bleeding during
surgery and in the postoperative period. In such situations,
the drug should be discontinued and the patients should
receive symptomatic treatment. To counter the deﬁciency
caused by a lack of antidote, other alternatives like using
unfractionated heparin (UFH) with prostacyclin, a potent
platelet aggregation inhibitor, have been explored. However,
the use of prostacyclin was associated with signiﬁcant hypotension [11]. A newer option where UFH was combined
with tiroﬁban, a short-acting GP IIb–IIIa inhibitor, has
shown to be promising with no evidence of thrombosis or
excessive hemorrhaging. In patients with a previous episode
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of HIT, the use of heparin is considered a safe option after
the platelet activating antibodies disappear. In an urgent
scenario, therapeutic plasma exchange has been used to
reduce antibody titres prior to the procedure.
While the use of argatroban in our case had a successful
outcome, there have been reports illustrating various
complications in the perioperative period with the use of this
medication [6]. More studies will be needed to determine
ideal dosage guidelines, and appropriate monitoring for the
use of argatroban as a heparin alternative in those patients
undergoing CPB with a HIT is needed.
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